SCHEMBL7650352

SCHEMBL7650352

C[C@H](N)O[PH](=O)O[C@H](C)N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1582044 1.00
Bromide SCHEMBL7624004 0.97
SCHEMBL11312346 0.79
SCHEMBL10411235 0.75
SCHEMBL5139831 0.75
SCHEMBL1191294 0.75
SCHEMBL9302436 0.74
SCHEMBL214833 0.72
SCHEMBL10596901 0.72
SCHEMBL6018532 0.69 TSHR (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6500811-B2 PROPHYLAXIS AND THERAPY OF DISORDERS IN THE COURSE OF WHICH AN INCREASED ACTIVITY OF MATRIX-DEGRADING ENZYMES IS INVOLVED; THESE INCLUDE DEGENERATIVE JOINT DISORDERS SUCH AS OSTEOARTHROSES AND DISORDERS OF CONNECTIVE TISSUE AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-12-31 US disclosed
US-20020082246-A1 Sulfonylaminophosphinic and sulfonylaminophosphonic acid derivatives, methods for their preparation and use AVENTIS PHARMA DEUTSCHLAND GMBH. 2002-06-27 US disclosed
US-6235727-B1 ENZYME INHIBITORS; MUSCULAR DISORDERS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-05-22 US disclosed